GET DAILY SIGNALSWhy Is Candel Therapeutics (CADL) Stock Down -28.13% Today?
Key Takeaways
- Exact move: CADL fell 28.13% to $6.03 in Friday morning trading, down $2.36 from the prior close of $8.39.
- Primary catalyst: Candel pushed the Biologics License Application for lead prostate cancer candidate aglatimagene besadenovec to mid-2027 from the fourth quarter of 2026.
- Secondary drivers: A widened third-quarter net loss of $21.9 million and a new $50 million at-the-market stock sale agreement with Jefferies revived dilution and cash-burn concerns.
- Analyst response: Stifel trimmed its target to $19 from $22, while Canaccord Genuity cut its target to $13 from $25; both maintained Buy ratings.
- Market context: The decline was almost entirely company-specific, with major indexes near flat and biotech benchmarks down only about 1% to 1.5%.
- Trading activity: Roughly 1.0 million shares changed hands in the first 15 minutes, well above the stock's typical full-day volume.
- News Significance Score: 76/100 — A major regulatory timeline setback collided with a rare move nearly eight times the stock's normal daily swing.
- Dive deeper into Price Targets, Earnings, and Forecast data for CADL on Tickeron's dedicated research pages.
- Explore Trending AI Robots to see which automated strategies are performing best in the current tape.
Opening Summary
Candel Therapeutics (CADL) is a Needham, Massachusetts-based clinical-stage biopharmaceutical company developing off-the-shelf viral immunotherapies for cancer, led by aglatimagene besadenovec in localized prostate cancer and linoserpaturev in recurrent high-grade glioma. Shares traded at $6.03 on Friday morning, a decline of 28.13%, or $2.36, from Thursday's closing price of $8.39. The stock is firmly lower and confirms a sharp bearish reaction to the company's third-quarter report and a six-month delay to the regulatory filing that underpins most of its valuation.
Regulatory Setback: BLA Timing Slips to Mid-2027
In its third-quarter release, Candel said it remains in dialogue with the U.S. Food and Drug Administration regarding the BLA for aglatimagene, but now expects to submit the application in the middle of 2027 rather than the fourth quarter of 2026. Management attributed the shift to timelines tied to certain assay refinements and cautioned that the final filing date depends on the outcome of those FDA discussions.
The filing is the central value driver for the company, which has described aglatimagene as a potential first new therapy in localized prostate cancer in more than two decades. Its pivotal trial showed a 41% reduction in the risk of recurrence or prostate cancer-specific death versus radiation alone in intermediate-risk patients after a median 58 months of follow-up. Pushing that milestone out by roughly two quarters resets expectations for a commercial launch into 2028, which is why the market reaction was so violent.
Wider Loss and a Fresh $50 Million ATM
Candel reported a third-quarter net loss of $21.9 million, versus $11.3 million a year earlier. Research and development spending nearly doubled to $15.6 million from $8.5 million, while general and administrative costs rose to $7.4 million from $4.7 million on higher headcount and commercial-readiness spending. The company ended September with $203.1 million in cash, which management expects to fund operations into the second quarter of 2028.
Separately, Candel disclosed a second amended open market sale agreement with Jefferies covering up to $50 million of common stock at a 3% commission, replacing a 2025 arrangement under which roughly $50 million had already been sold. For investors already absorbing a slower approval path, the prospect of additional share issuance weighed on sentiment.
Analyst Price Target Cuts Reinforce the Rerating
Wall Street moved quickly. Stifel's Stephen Willey lowered his target to $19 from $22 while keeping a Buy rating, calling the disclosure incrementally negative and noting it resets commercialization expectations to mid-fiscal 2028 and raises perceived regulatory risk. Canaccord Genuity cut its target to $13 from $25, also maintaining a Buy, and suggested the delay may relate to differences between the product used in Phase 3 trials and the commercial version. Even after the cuts, targets sit far above the current share price, a sign that the debate is about timing and probability rather than the underlying science.
Market Context and Trading Activity
This was an idiosyncratic selloff, not a sector event. The S&P 500 and Nasdaq-100 were essentially flat, while the XBI and IBB biotech exchange-traded funds slipped roughly 1.5% and 1.2% respectively, a fraction of CADL's loss. Volume was heavy: about 1.0 million shares traded in the first 15 minutes, against a typical full-session average near 0.6 million, indicating institutional repositioning rather than retail noise.
The stock gapped open at $5.20 — a level not seen in months — before buyers stepped in to lift it back toward $6.03, leaving a wide opening range. The gap decisively broke the $8.00 support zone that had held through October and pushed shares well below their 50-day moving average, which sits near $9.90.
News Significance Score
The score runs from 0, meaning no meaningful news and a move typical for the stock, to 100, meaning transformative news and an extreme, rare price move. Here, the verified catalyst was substantial: a six-month delay to the single regulatory filing that defines the investment case, paired with a wider loss and a renewed $50 million share-sale facility, all for a company worth roughly $460 million after the drop. The price move was equally unusual — about 7.7 times the stock's average absolute daily change of 3.6% over the past 60 sessions, and larger than any single-session move in that stretch, with the heaviest early volume in months. Those two factors combine to 76 out of 100.
What Comes Next for CADL
Attention now shifts to the FDA dialogue and any clarity on the assay refinements behind the revised filing date. Investors will also track process validation testing at the company's contract manufacturer, which management says is underway for both drug substance and drug product, and any updates on the Phase 3 Aurora study of aglatimagene in non-small cell lung cancer. Poster data presented at SITC earlier this month, including systemic T-cell activation and survival findings, remain a supportive offset.
Financing is the key risk. Cash is guided to last into the second quarter of 2028, but a mid-2027 filing and a launch beyond that window tighten the margin between runway and revenue, and the new at-the-market facility provides a ready mechanism for dilution. With the stock having traded between $4.35 and $14.00 over the past year, volatility is likely to stay elevated until the filing path is de-risked.
Trending AI Robots
Tickeron's Trending AI Robots page curates the strongest-performing automated trading strategies in current market conditions from a library covering hundreds of bots and thousands of tickers. Because each bot differs in strategy, timeframe, performance metrics, and traded symbols, the featured list offers a practical starting point for comparing approaches side by side. For readers tracking volatile names like CADL, it is a useful next stop to see which models are adapting best to today's tape.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
CADL saw its Stochastic Oscillator recovers from the overbought zone
The Stochastic Oscillator for CADL moved out of overbought territory on November 12, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 49 similar instances where the indicator exited the overbought zone. In 44 of the 49 cases the stock moved lower. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CADL as a result. In 86 of 102 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 84%.
The Moving Average Convergence Divergence Histogram (MACD) for CADL turned negative on November 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 41 similar instances when the indicator turned negative. In 34 of the 41 cases the stock turned lower in the days that followed. This puts the odds of success at 83%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CADL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Aroon Indicator for CADL entered a downward trend on November 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator entered the oversold zone -- be on the watch for CADL's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
Following a +18.04% 3-day Advance, the price is estimated to grow further. Considering data from situations where CADL advanced for three days, in 213 of 252 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
CADL may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 32 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 58 (best 1 - 100 worst), indicating steady price growth. CADL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 83 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.308) is normal, around the industry mean (3.498). P/E Ratio (-5.952) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CADL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement